Latest Articles
M2 Macrophages are Major Mediators of Germline Risk of Endometriosis and Explain Pleiotropy with Comorbid Traits.
Endometriosis is a common gynecologic condition that causes chronic life-altering symptoms including pain, infertility, and elevated cancer risk. There is an urgent need for new non-hormonal targeted therapeutics to treat …
Published: Nov. 22, 2024, midnight
Lisata Therapeutics CEO David Mazzo on Q3 results; updates on key clinical trials and partnerships - Proactive Investors UK
Lisata Therapeutics CEO David Mazzo on Q3 results; updates on key clinical trials and partnerships Proactive Investors UK
Published: Nov. 14, 2024, 4:39 p.m.
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights GlobeNewswire
Published: Nov. 13, 2024, 12:15 p.m.
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update The Manila Times
Published: Nov. 12, 2024, 9:12 p.m.
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results The Manila Times
Published: Nov. 7, 2024, 12:14 p.m.
Lisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapy - ICYMI - Proactive Investors USA
Lisata Therapeutics partners with University of Cincinnati to investigate endometriosis therapy - ICYMI Proactive Investors USA
Published: Nov. 2, 2024, noon
Lisata Therapeutics, University of Cincinnati explore combination treatment for Endometriosis - ca.proactiveinvestors.com
Lisata Therapeutics, University of Cincinnati explore combination treatment for Endometriosis ca.proactiveinvestors.com
Published: Oct. 31, 2024, 5:16 p.m.
Lisata Therapeutics, University of Cincinnati explore combination treatment for Endometriosis - Proactive financial news
Lisata Therapeutics, University of Cincinnati explore combination treatment for Endometriosis Proactive financial news
Published: Oct. 31, 2024, 5:16 p.m.
Lisata Therapeutics, University of Cincinnati explore combination treatment for Endometriosis - Proactive Investors USA
Lisata Therapeutics, University of Cincinnati explore combination treatment for Endometriosis Proactive Investors USA
Published: Oct. 31, 2024, 5:16 p.m.
Lisata Therapeutics Announces Sponsored Preclinical - GlobeNewswire
Lisata Therapeutics Announces Sponsored Preclinical GlobeNewswire
Published: Oct. 28, 2024, 2:42 p.m.
Link copied to clipboard!